LYCA Lycia Therapeutics, Inc. stock chart & analysis

Conviction 12HealthcareScan · Tue, Oct 27, 2026

Lycia Therapeutics, Inc. (LYCA) closed at $26.00 (-9.88%) on Oct 27, 2026. -28.7% from its 52-week high, -13.3% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).

LYCA$26.00-9.88%

ResistanceSupportVol 14

Oct 23Oct 26Oct 27

Lycia Therapeutics, Inc.Biological Products, (No Diagnostic Substances)

Price26.00

Change-9.88%

Gap-4.68%

Rel volume0.02×

Avg volume1.1M

Avg $ vol32.5M

SMA 20—

SMA 50—

SMA 200—

Price vs 50—

Price vs 200—

MA stack—

50/200 cross—

Supertrend—

RSI (14)—

MACD hist—

MACD cross—

Stoch %K / %D— / —

ADX (14)—

+DI / −DI— / —

RSI divergence—

MACD divergence—

ATR %—

ADR %—

52w high36.49

52w low22.19

From 52w high-28.75%

Above 52w low+17.17%

New 52w highNo

SqueezeOff

Bollinger width—

%B—

Donchian pos—

Donchian high—

Donchian low—

AVWAP (52w high)—

vs AVWAP high—

AVWAP (52w low)—

vs AVWAP low—

OBV trend—

Chaikin MF (20)—

Today vs 20d0.02×

Avg vol (14d)—

Avg vol (20d)1.1M

Avg $ vol (20d)32.5M

Market cap—

RS Rating—

RS 3m (vs SPY)—

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank—

1 week—

1 month—

3 months—

6 months—

1 year—

YTD-13.33%

P/E—

P/B—

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current—

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value—

Revenue—

Net income—

Gross profit—

Free cash flow—

IndustryBiological Products, (No Diagnostic Substances)

ExchangeNasdaq

Shares out—

Employees—

Listed—

Free float7.81M

Float %15.0%

Short interest—

Days to cover—

Short volume33.5%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction12 / 100

Pattern quality—

Tech rank—

Group rank—

Status laneNo active setup

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirm—

LYCA technical analysis

Volume and volatility

Volume on the latest session ran 0.0× its 20-day average. It trades about $32.5M a day on average.

Key levels

The 52-week range is $22.19 to $36.49; price is 28.7% below the high and 17.2% above the low.

Performance

LYCA returned -13.3% (year to date).

About Lycia Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)

Insider activity

SEC Form 4 transactions in LYCA

Insider	Side	Shares	Value	Traded	Filed
Fischer Laurent Director · Stock Option (Right to Buy) · 2026-10-22	Grant	20K	—	2026-10-22	2026-10-26
Henderson Jane Director · Stock Option (Right to Buy) · 2026-10-22	Grant	20K	—	2026-10-22	2026-10-26
RIEFLIN WILLIAM JL Director · Stock Option (Right to Buy) · 2026-10-22	Grant	20K	—	2026-10-22	2026-10-26
Lee Chin Hyok Chief Medical Officer · Stock Option (Right to Buy) · 2026-08-11	Grant	73.19K	—	2026-08-11	2026-10-26
RIEFLIN WILLIAM JL Director · Stock Option (Right to Buy) · 2026-08-11	Grant	24.84K	—	2026-08-11	2026-10-26
Trombley Aetna Wun President and CEO · Stock Option (Right to Buy) · 2026-08-11	Grant	443.59K	—	2026-08-11	2026-10-26
Staben Steven Chief Scientific Officer · Stock Option (Right to Buy) · 2026-08-11	Grant	110.9K	—	2026-08-11	2026-10-26
Bachrodt Amy Chief Financial Officer · Stock Option (Right to Buy) · 2026-08-11	Grant	399.75K	—	2026-08-11	2026-10-26
Touami Sofia Chief Business Officer · Stock Option (Right to Buy) · 2026-08-11	Grant	68.75K	—	2026-08-11	2026-10-26
Fischer Laurent Director · Stock Option (Right to Buy) · 2026-08-11	Grant	13.31K	—	2026-08-11	2026-10-26

SEC filings

EDGAR filings in LYCA · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.